A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
about
Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancerMuscle-invasive urothelial bladder cancer: an update on systemic therapyGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsDesign, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffoldMolecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesA place for precision medicine in bladder cancer: targeting the FGFRs.Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancerIs fibroblast growth factor receptor 4 a suitable target of cancer therapy?Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications.In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancerCrystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455FGFR1 amplification in squamous cell carcinoma of the lung.A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).FGF19 functions as autocrine growth factor for hepatoblastomaThe anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer.In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages.Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.Targeting FGF receptors in colorectal cancer: from bench side to bed side.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Targeting FGFR in Squamous Cell Carcinoma of the Lung.In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?FGFR-targeted therapeutics for the treatment of breast cancer.A FGFR1 inhibitor patent review: progress since 2010.Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cellsInhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis.Advances and challenges in targeting FGFR signalling in cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Lineage-specific biomarkers predict response to FGFR inhibition.Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
P2860
Q26764932-8773B5DA-26C4-4E99-877A-F31702B619EDQ26775780-6CD5D607-12AF-494A-AD49-2BEDE5F88739Q26998790-4A8D3D47-8C83-4C6F-99F9-7239CD9F3D7BQ27701029-014508BB-0CC0-455F-8404-1EC2C469020AQ28079232-8C7BAFF6-5C3F-409F-BA01-376BD1FBB432Q30249143-66609EAF-F562-4535-A071-544C992A021DQ33733751-61BBF98E-A022-406C-9905-56C0824BA200Q33751398-1C697D20-5B8E-4760-ABEF-166B4DE14B66Q34525925-15C0340B-F8A5-41CA-A83B-BBB7A70C14A9Q34658030-EB598780-C2E0-44F1-994A-75E3CB543635Q35206634-7DA2B634-1D8E-48CB-83B0-75F2ACB5678EQ35870855-B857EDBB-49D9-4BB5-96DA-0D8DCC2CF6CCQ36129968-7DFAD20C-EEC8-4919-A53A-979F8B45461DQ36406190-58A17384-9A2E-45C0-BB99-0C70280E0608Q36594039-5F6CD419-910C-4578-975A-D628EC0C5738Q36983860-53E9DF47-B712-4C0A-9760-866331B298FFQ37033310-4443C992-291A-45DF-84F4-84D7E804D184Q37392801-09F05CE6-BCB7-4BB6-B2E9-FBCB489AC3D1Q37515231-AECF7636-FCA9-4D18-B309-C1B02F7AB1ADQ37567109-5D518AF4-E694-4C7F-AD75-04F2740734CFQ37580305-0E68EE6E-4904-430A-A075-952B7C56C36BQ37697253-34720BDF-4262-4031-9035-9A895CD4DE10Q37996468-A6D8835A-1912-4CA8-83A3-45A2D9FE7B50Q38087392-F37A09AC-3980-4C1E-8ED1-38E6015EED7EQ38130312-63998E9B-532A-4DD2-A820-B6DE5D19235AQ38153418-5EF35626-8A1A-47C7-BFC3-A5F112F25030Q38285703-46D7226F-335E-47AA-8BF4-B281B30EBB5AQ38465837-DFDDF6CA-970C-450B-A292-7ABC07F74014Q38602669-237B522B-667C-4CE6-B484-22F5618DD873Q38690050-83985E22-2769-49FC-8815-907FAC8002A5Q38734306-582E0371-372F-4826-8539-1DC3AF5D3C79Q38741697-2EF63004-BFAE-4B6D-8754-31A6E990DFE2Q38766035-CB2211F9-9DEC-429D-88D3-25AB3EFCC4F7Q38782612-69EE6731-0449-4A6A-9874-BED8F41939CFQ38939465-924417C9-6E0C-4B23-8B23-0664328745F0Q39036666-54CA1C09-999C-4931-B94D-8D437E9955D7Q39183442-42D62849-AA0A-4246-8C00-26E5DE16FEA5Q39226762-1C50D33E-7891-455C-A86D-3193BE855EDDQ39228091-CAC889DA-5044-4A64-A4D3-55B5425AF191Q39325740-36AFB410-BC34-4BE5-BFF7-9EC37EFDEC88
P2860
A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A novel, selective inhibitor o ...... everal tumor xenograft models.
@en
A novel, selective inhibitor o ...... everal tumor xenograft models.
@nl
type
label
A novel, selective inhibitor o ...... everal tumor xenograft models.
@en
A novel, selective inhibitor o ...... everal tumor xenograft models.
@nl
prefLabel
A novel, selective inhibitor o ...... everal tumor xenograft models.
@en
A novel, selective inhibitor o ...... everal tumor xenograft models.
@nl
P2093
P1476
A novel, selective inhibitor o ...... everal tumor xenograft models.
@en
P2093
Daohong Chen
Denis J McCann
Genshi Zhao
Hong-Yu Li
James R Henry
Karen Huss
Laura Bloem
Mohammad Zia-Ebrahimi
Sheng-Bin Peng
Wei-Ying Li
P304
P356
10.1158/1535-7163.MCT-11-0306
P577
2011-09-07T00:00:00Z